New Hope for PTSD Treatment,
May 16, 2019

Newly Identified Neural Circuit May Be Target for Future PTSD Treatments

A research team funded by the Hope for Depression Research Foundation (HDRF) has identified a specific circuit of young adult-born neurons in the brain that plays a key role in the recognition of a safe versus hazardous situations.

Their findings, recently published in Science, could pave the way for more targeted treatments for conditions such as PTSD that are associated with hypervigilance and recurrent distressing memories.

Breaking Bad Habits,
April 18, 2019

As we head into summer, many of us are taking stock of habits we resolved to change at the start of the year. Perhaps we are trying to eat better, start a new exercise regime, get to bed earlier, or quit smoking.

Despite our resolve, we have a hard time sticking to the program. In this letter we are going to address what makes us have such a hard time changing our habits, and how we might be able to improve.

FDA Approves New Drug for Postpartum Depression,
March 22, 2019

One in nine women in the United States experience symptoms of postpartum depression, a terrifying illness that is often difficult to treat.

That’s why we’re excited by news that the FDA has approved Brexanolone, a drug over 40 years in the making that is the first ever to specifically target the condition. The approval of Brexanolone is a cause for celebration for the entire field of neuroscience.

Click here to read the full article…

Audrey Gruss Honored as Woman of Distinction by Palm Beach Atlantic University,
March 5, 2019

We are proud to announce that Hope for Depression Research (HDRF) founder and Chair Audrey Gruss recently was honored at the 2019 Women of Distinction luncheon by Palm Beach Atlantic (PBA) University in Florida.

Novel Depression Treatment in the News,
February 15, 2019

A new antidepressant is expected to soon be approved by the Food and Drug Administration.

The New York Times reported yesterday that an advisory panel at the agency has voted in favor of recommending approval of the new drug, the nasal spray Esketamine, to treat severely depressed patients.